Protocols
ADP-0055-001-MAGE-A4-SURPASS Phase I OPEN TO ACCRUAL
A Phase 1 Dose Escalation Study to Assess Safety and Efficacy of ADP-A2M4CD8 as Monotherapy or in Combination with Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects with MAGE-A4 Positive Tumors
IIT-GEORGE-I-PREDICT Phase I/II OPEN TO ACCRUAL
An Open-Label, Navigational Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy for Patients with Aggressive Malignancies and Poor Prognoses